FDA peptide votes could open the door to more unproven drugs: ‘Pandora’s box’

A FDA panel recommended two more unproven peptides, raising questions about whether the agency was weakening the guardrails designed to keep untested drugs from reaching patients.

A Food and Drug Administration advisory committee on Friday recommended allowing two more unproven peptides to be compounded, capping a two-day meeting that raised questions about whether the agency was weakening the guardrails designed to keep untested drugs from reaching patients.

Subscribe to read this story ad-free

Get unlimited access to ad-free articles and exclusive content.

Just a moment.

We are getting your experience ready.